JP2010504950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504950A5 JP2010504950A5 JP2009529761A JP2009529761A JP2010504950A5 JP 2010504950 A5 JP2010504950 A5 JP 2010504950A5 JP 2009529761 A JP2009529761 A JP 2009529761A JP 2009529761 A JP2009529761 A JP 2009529761A JP 2010504950 A5 JP2010504950 A5 JP 2010504950A5
- Authority
- JP
- Japan
- Prior art keywords
- aripiprazole
- hours
- released
- administration
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 47
- 229960004372 aripiprazole Drugs 0.000 claims 47
- 239000000203 mixture Substances 0.000 claims 18
- 238000013270 controlled release Methods 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000007922 dissolution test Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 229940125723 sedative agent Drugs 0.000 claims 3
- 239000000932 sedative agent Substances 0.000 claims 3
- -1 seed Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 208000030963 borderline personality disease Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000025434 cerebellar degeneration Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000036546 leukodystrophy Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 claims 1
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 241000238097 Callinectes sapidus Species 0.000 claims 1
- 208000022526 Canavan disease Diseases 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- 208000026845 Cochlear disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- GUTXTARXLVFHDK-UHFFFAOYSA-N Haloperidol decanoate Chemical compound C1CC(OC(=O)CCCCCCCCC)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 GUTXTARXLVFHDK-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010069141 Septic encephalopathy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 208000011641 Spinocerebellar disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 229960004538 alprazolam Drugs 0.000 claims 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 1
- 229960003036 amisulpride Drugs 0.000 claims 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229960004782 chlordiazepoxide Drugs 0.000 claims 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 chlorpromazine Drugs 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- 229960004362 clorazepate Drugs 0.000 claims 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000013283 epinephrine uptake Effects 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960005007 haloperidol decanoate Drugs 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229960001078 lithium Drugs 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000003458 metachromatic effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000020469 nerve plexus disease Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 230000009994 neurotransmitter pathway Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 206010029864 nystagmus Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 229960004535 oxazepam Drugs 0.000 claims 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- 230000001936 parietal effect Effects 0.000 claims 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229960000964 phenelzine Drugs 0.000 claims 1
- 201000006380 plexopathy Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 208000006473 polyradiculopathy Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960003770 reboxetine Drugs 0.000 claims 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
- 210000001044 sensory neuron Anatomy 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 229960003660 sertraline hydrochloride Drugs 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 230000001720 vestibular Effects 0.000 claims 1
- 229960001255 viloxazine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0618879.1A GB0618879D0 (en) | 2006-09-26 | 2006-09-26 | Pharmaceutical compositions |
| PCT/GB2007/003677 WO2008038003A2 (en) | 2006-09-26 | 2007-09-26 | Pharmaceutical compositions of aripiprazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504950A JP2010504950A (ja) | 2010-02-18 |
| JP2010504950A5 true JP2010504950A5 (enExample) | 2010-12-09 |
Family
ID=37421592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529761A Pending JP2010504950A (ja) | 2006-09-26 | 2007-09-26 | 医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8575172B2 (enExample) |
| EP (1) | EP2066325B1 (enExample) |
| JP (1) | JP2010504950A (enExample) |
| KR (1) | KR20090065514A (enExample) |
| AT (1) | ATE540680T1 (enExample) |
| AU (1) | AU2007301742B2 (enExample) |
| CA (1) | CA2664455A1 (enExample) |
| DK (1) | DK2066325T3 (enExample) |
| ES (1) | ES2395119T3 (enExample) |
| GB (1) | GB0618879D0 (enExample) |
| IL (1) | IL197574A (enExample) |
| PT (1) | PT2066325E (enExample) |
| WO (1) | WO2008038003A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| UA104869C2 (uk) | 2008-07-16 | 2014-03-25 | Ріхтер Гедеон Нірт. | Фармацевтичні композиції, що містять ліганди рецептора дофаміну |
| US8372808B2 (en) * | 2008-10-31 | 2013-02-12 | Wisconsin Alumni Research Foundation | Suppression of glial fibrillary acidic protein |
| JP5664871B2 (ja) * | 2009-06-19 | 2015-02-04 | 株式会社 メドレックス | アリピプラゾールと有機酸を有効成分とする外用剤組成物 |
| CN102670553A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 盐酸文拉法辛渗透泵控释片 |
| WO2012129232A1 (en) * | 2011-03-21 | 2012-09-27 | Conour James | Compositions for the treatment of psychotic or neurological disorders |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| WO2013175508A2 (en) | 2012-05-24 | 2013-11-28 | Medreich Limited | Stable pharmaceutical composition of aripiprazole |
| EP2968996A4 (en) * | 2013-03-15 | 2017-03-08 | Ameritox Limited Partnership | Methods of monitoring for adherence to aripiprazole therapy |
| CN103393594A (zh) * | 2013-08-22 | 2013-11-20 | 万特制药(海南)有限公司 | 一种新的阿立哌唑的制剂组合物 |
| US10525057B2 (en) * | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| CN103536594A (zh) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途 |
| US20190070174A1 (en) * | 2016-03-10 | 2019-03-07 | The Regents Of The University Of Michigan | Methods of treating neurodegenerative diseases |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HUP1700253A1 (hu) | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
| KR20200110317A (ko) | 2017-12-05 | 2020-09-23 | 선오비온 파마슈티컬스 인코포레이티드 | 결정형 및 이의 제조 방법 |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| CN110025572A (zh) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | 月桂酰阿立哌唑混悬剂及其制备方法 |
| EP3789029B1 (en) * | 2018-05-04 | 2024-05-08 | Korea Institute of Radiological & Medical Sciences | Radiation sensitivity enhancing composition containing aripiprazole as active ingredient |
| US12138363B2 (en) * | 2018-10-04 | 2024-11-12 | École Polytechnique Fédérale de Lausanne | Cross-linkable polymer, hydrogel, and method of preparation thereof |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| JP2024502431A (ja) * | 2020-12-31 | 2024-01-19 | レイク オハラ エルエルシー | 肥満患者における、ブレクスピプラゾールを用いた精神疾患の治療方法 |
| KR102525213B1 (ko) | 2021-01-13 | 2023-04-25 | 아주대학교산학협력단 | Qr 코드가 적용된 구강붕해필름 및 3d 프린팅 기술을 이용한 이의 제조방법 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| GB9611328D0 (en) | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| MXPA03006003A (es) | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| DE60234873D1 (de) | 2001-06-19 | 2010-02-04 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| CA2475839A1 (en) | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
| EP1491207A4 (en) * | 2002-03-28 | 2006-02-08 | Takeda Pharmaceutical | NEW SCREENING PROCESS |
| DE10224170A1 (de) * | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
| CA2494109A1 (en) | 2002-07-29 | 2004-02-05 | Potomac, Pharma, Llc. | Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| RU2342931C2 (ru) | 2002-08-20 | 2009-01-10 | Бристол-Маерс Сквибб Компани | Состав на основе комплекса арипипразола |
| CA2503381A1 (en) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| WO2004083183A1 (en) | 2003-03-21 | 2004-09-30 | Hetero Drugs Limited | Novel crystalline forms of aripiprazole |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
| JP2007509155A (ja) * | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
| CA2543242C (en) * | 2003-10-23 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| CA2547639A1 (en) | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| JP5546717B2 (ja) | 2003-12-16 | 2014-07-09 | テバ ファーマシューティカル インダストリーズ リミティド | アリピプラゾール結晶質形態を調製する方法 |
| BRPI0507250A (pt) | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| EP1740181A1 (en) * | 2004-04-22 | 2007-01-10 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| JP2007537232A (ja) | 2004-05-11 | 2007-12-20 | ファイザー・プロダクツ・インク | 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ |
| TWI338583B (en) * | 2004-05-20 | 2011-03-11 | Otsuka Pharma Co Ltd | Solid pharmaceutical formulation |
| WO2006000222A2 (en) | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| WO2006012237A2 (en) | 2004-06-25 | 2006-02-02 | Shanghai Institute Of Pharmaceutical Industry | Aripiprazole crystaline forms and associated methods |
| GB0417702D0 (en) | 2004-08-09 | 2004-09-08 | Merck Sharp & Dohme | New uses |
| CN101087760B (zh) | 2004-11-18 | 2011-09-28 | 斯索恩有限公司 | 结晶的阿立哌唑溶剂化物 |
| AU2005319367B2 (en) | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1858514B1 (en) | 2005-03-17 | 2014-11-26 | Synthon B.V. | Pharmaceutical tablets of crystalline type ii aripiprazole |
| EP1879865A1 (en) | 2005-04-15 | 2008-01-23 | Medichem S.A. | Syntheses and preparations of polymorphs of crystalline aripiprazole |
| HUP0500683A3 (en) | 2005-07-14 | 2009-03-30 | Egis Gyogyszergyar Nyilvanosan | New arylpiprazole salts for producing pharmaceutical composition |
| US20070148100A1 (en) * | 2005-09-15 | 2007-06-28 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| EP1808164B2 (en) | 2006-01-05 | 2018-07-04 | Teva Pharmaceutical Industries Ltd | Wet granulation method for preparing pharmaceutical compositions of aripiprazole |
| EP1808165B1 (en) | 2006-01-05 | 2009-04-29 | Teva Pharmaceutical Industries Ltd | Dry formulations of aripiprazole |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
-
2006
- 2006-09-26 GB GBGB0618879.1A patent/GB0618879D0/en not_active Ceased
-
2007
- 2007-09-26 CA CA002664455A patent/CA2664455A1/en not_active Abandoned
- 2007-09-26 AT AT07823939T patent/ATE540680T1/de active
- 2007-09-26 JP JP2009529761A patent/JP2010504950A/ja active Pending
- 2007-09-26 PT PT07823939T patent/PT2066325E/pt unknown
- 2007-09-26 ES ES07823939T patent/ES2395119T3/es active Active
- 2007-09-26 KR KR1020097006098A patent/KR20090065514A/ko not_active Abandoned
- 2007-09-26 DK DK07823939.9T patent/DK2066325T3/da active
- 2007-09-26 EP EP07823939A patent/EP2066325B1/en not_active Revoked
- 2007-09-26 WO PCT/GB2007/003677 patent/WO2008038003A2/en not_active Ceased
- 2007-09-26 US US12/443,036 patent/US8575172B2/en not_active Expired - Fee Related
- 2007-09-26 AU AU2007301742A patent/AU2007301742B2/en not_active Ceased
-
2009
- 2009-03-12 IL IL197574A patent/IL197574A/en active IP Right Grant
-
2013
- 2013-10-14 US US14/053,117 patent/US20140044786A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504950A5 (enExample) | ||
| US20240217945A1 (en) | Enantiomeric entactogen compositions and their use | |
| Dell’Osso et al. | The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects | |
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| US20130281523A1 (en) | Low dose cannabinoid medicaments | |
| CN115521217A (zh) | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 | |
| JP7245509B2 (ja) | 吃音を治療するための融合ベンズアゼピン | |
| JP2010523640A5 (enExample) | ||
| WO2007117431A2 (en) | Use of rasagiline for the treatment of restless legs syndrome | |
| Saini et al. | Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review | |
| JP2017534613A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| PT1745786E (pt) | Compostos neuroprotetores e composições farmacêuticas que os compreendem | |
| WO2015153971A1 (en) | Methods of treating sleep disorders associated with neurodegenerative diseases | |
| Nishino | Modes of action of drugs related to narcolepsy: pharmacology of wake-promoting compounds and anticataplectics | |
| Gonçalves et al. | Drug-induced sleepiness and insomnia: an update | |
| Dhawan et al. | Auvelity: A New Era in Medicine-Unraveling the Multifaceted Benefits of Dextromethorphan/Bupropion Combination | |
| US20060217394A1 (en) | Treatment of anhedonia | |
| JP2022511755A (ja) | 精神障害の治療のためのガボキサドールとリチウムとの組み合わせ | |
| Tremor | The Underrecognized Movement Disorders Associated With Mood Stabilizers | |
| CN111670041A (zh) | 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合 | |
| Wilson | Pharmacology of psychiatric drugs and their effects on sleep | |
| ES2969657T3 (es) | Tratamiento de trastorno de síndrome postraumático | |
| Rizek et al. | Management of Advanced Parkinson’s Disease | |
| Shrivastava | Pharmacological Agents Used in Various Sleep Disorders | |
| Hahn | Hypnotics: Pharmacology |